A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Copaxone and its generic form, Glatopa, may lead to anaphylaxis even in patients who’ve been taking the medication for months without incident. The FDA warns that the injectable MS drugs Copaxone and ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

The FDA on Tuesday approved Novartis’ generic version of Teva Pharmaceutical’s best-selling multiple sclerosis drug, Copaxone, reports Reuters. Here are three things to know. 1. Glatopa, manufactured ...

WASHINGTON (AP) — The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world’s best-selling multiple sclerosis treatment.

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. BRUSSELS (AP) — The European Commission said ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

Copaxone (glatiramer acetate injection) has potential interactions with other medications. These interactions could cause harmful effects. Copaxone is used in adults to treat relapsing forms of ...

BRUSSELS — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple ...